Very true, and Jagx has exclusivity on the market until 2035 as well as on the Generic for 7 years after... so its tied up and will be a massive revenue stream once approved. With the product already FDA approved for HIV treatment, after completing a Phase I safety study and both Phase II and III human safety efficacy trials , its hard to imagine that it would not get FDA approval for Cancer treatment.
News 
Market Data 
Discover 
